Abstract

We develop and validate a radiomics model based on multiparametric magnetic resonance imaging (MRI) in the classification of the pulmonary lesion and identify optimal machine learning methods. This retrospective analysis included 201 patients (143 malignancies, 58 benign lesions). Radiomics features were extracted from multiparametric MRI, including T2-weighted imaging (T2WI), T1-weighted imaging (TIWI), and apparent diffusion coefficient (ADC) map. Three feature selection methods, including recursive feature elimination (RFE), t test, and least absolute shrinkage and selection operator (LASSO), and three classification methods, including linear discriminate analysis (LDA), support vector machine (SVM), and random forest (RF) were used to distinguish benign and malignant pulmonary lesions. Performance was compared by AUC, sensitivity, accuracy, precision, and specificity. Analysis of performance differences in three randomly drawn cross-validation sets verified the stability of the results. For most single MR sequences or combinations of multiple MR sequences, RFE feature selection method with SVM classifier had the best performance, followed by RFE with RF. The radiomics model based on multiple sequences showed a higher diagnostic accuracy than single sequence for every machine learning method. Using RFE with SVM, the joint model of T1WI, T2WI, and ADC showed the highest performance with AUC = 0.88 ± 0.02 (sensitivity 83%; accuracy 82%; precision 91%; specificity 79%) in test set. Quantitative radiomics features based on multiparametric MRI have good performance in differentiating lung malignancies and benign lesions. The machine learning method of RFE with SVM is superior to the combination of other feature selection and classifier methods. • Radiomics approach has the potential to distinguish between benign and malignant pulmonary lesions. • Radiomics model based on multiparametric MRI has better performance than single-sequence models. • The machine learning methods RFE with SVM perform best in the current cohort.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.